Auraptene Boosts the Efficacy of the Tamoxifen Metabolites Endoxifen and 4-OH-Tamoxifen in a Chemoresistant ER+ Breast Cancer Model

• Main Authors: Angel Pulido-Capiz (Author), Brenda Chimal-Vega (Author), Luis Pablo Avila-Barrientos (Author), Alondra Campos-Valenzuela (Author), Raúl Díaz-Molina (Author), Raquel Muñiz-Salazar (Author), Octavio Galindo-Hernández (Author), Victor García-González (Author)
• Format: Book
• Published: MDPI AG, 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Approximately 80% of breast cancer (BC) cases are estrogen receptor positive (ER+) and sensitive to hormone treatment; Tamoxifen is a prodrug, and its main plasmatic active metabolites are 4-hydroxytamoxifen (4-OH Tam) and endoxifen. Despite the effectiveness of tamoxifen therapy, resistance can be...